Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer

Improving response to epidermal growth factor receptor (EGFR)-targeted therapies in patients with advanced wild-type (WT) RAS colorectal cancer (CRC) remains an unmet need. In this preclinical work, we evaluated a new therapeutic combination aimed at enhancing efficacy by targeting cancer cell metab...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Allison S., Geng, Ling, Zhao, Ping, Fu, Allie, Schulte, Michael L., Graves-Deal, Ramona, Washington, M. Kay, Berlin, Jordan, Coffey, Robert J., Manning, H. Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348062/
https://www.ncbi.nlm.nih.gov/pubmed/32652471
http://dx.doi.org/10.1016/j.tranon.2020.100828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348062/
https://www.ncbi.nlm.nih.gov/pubmed/32652471
http://dx.doi.org/10.1016/j.tranon.2020.100828

Ejemplares similares